| Not Yet Recruiting | Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer NCT07470489 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial NCT07485569 | Radboud University Medical Center | Phase 1 |
| Recruiting | XL092 and Cemiplimab in BRAF WT Thyroid Cancer NCT06902376 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Sacituzumab govitEcan in THYroid Cancers NCT06235216 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Not Yet Recruiting | Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences NCT05819593 | Power Life Sciences Inc. | — |
| Recruiting | Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer NCT06374602 | Saint Petersburg State University, Russia | Phase 2 |
| Recruiting | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on NCT06362694 | Saint Petersburg State University, Russia | Phase 2 |
| Recruiting | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) NCT06079333 | Leiden University Medical Center | Phase 2 |
| Unknown | European Multicenter Study on Surgical Management of Advanced Thyroid Cancer NCT05796960 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Unknown | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation NCT05102292 | Shanghai Henlius Biotech | Phase 1 / Phase 2 |
| Terminated | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors NCT04579757 | Hutchmed | Phase 1 / Phase 2 |
| Unknown | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) NCT04574817 | Taizhou Hanzhong biomedical co. LTD | Phase 2 |
| Completed | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CAB NCT04400474 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Active Not Recruiting | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer NCT04420754 | AffyImmune Therapeutics, Inc. | Phase 1 |
| Completed | Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer NCT04552769 | Stanford University | Phase 2 |
| Active Not Recruiting | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer NCT04238624 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) NCT05696548 | National Cancer Center Hospital East | Phase 2 |
| Active Not Recruiting | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer NCT03085056 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Completed | Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer NCT02688608 | Saad A Khan | Phase 2 |
| Completed | Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer NCT02726503 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Phase 2 |
| Completed | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or R NCT02244463 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Phase I/II Study of PDR001 in Patients With Advanced Malignancies NCT02404441 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Withdrawn | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer NCT01701349 | Mateon Therapeutics | Phase 3 |
| Completed | Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer NCT02152137 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Unknown | interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) NCT01774279 | Velindre NHS Trust | — |
| Completed | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplast NCT01240590 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel NCT00603941 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Terminated | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer NCT00507429 | Mateon Therapeutics | Phase 2 / Phase 3 |
| Completed | Review of Multimodality Management of Anaplastic Thyroid Cancer NCT00280852 | Alberta Health services | — |
| Terminated | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer NCT00126568 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer NCT00095693 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497 | National Cancer Institute (NCI) | N/A |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |